Every cancer is distinct. Let’s handle it accordingly
Knowing a patient’s biomarker profile can uncover novel targets for therapies.
Individuals with advanced or late stage cancers.
Individuals who have tested negative for single gene mutations and require a more comprehensive tumor profiling.
Individuals with cancers of unknown primary origin.
Individuals with inadequate amount of tissue or unobtainable tissue for biopsy.
Patients newly diagnosed with Non-Small Cell Lung Cancer (NSCLC).
NSCLC patients with drug resistance to multiple types of chemotherapy.
NSCLC patients planning to use targeted therapy.
NSCLC patients who are treated with chemotherapies and would like to know the efficacy and toxicity of these drugs.
Patients newly diagnosed with Colorectal Cancer (CRC).
CRC patients with drug resistance to multiple types of chemotherapy.
CRC patients planning to use targeted therapy.
CRC patients who are treated with chemotherapies and would like to know the efficacy and toxicity of these drugs.
Breast cancer patients with HER2-negative tumors.
Breast cancer patients with triple-negative tumors.
Patients with platinum-sensitive or platinum-resistant ovarian cancer who have been treated with two or more lines of chemotherapy.